See the DrugPatentWatch profile for Bosutinib
When does the bosutinib patent expire?
Bosutinib’s patent “expiry” depends on which patent family and which jurisdiction you mean (the drug may still have protection from additional patents or regulatory exclusivities even after an initial filing window ends). Public patent datasets are usually the fastest way to narrow down the specific end dates by product strength/formulation and country.
To check the most relevant listed dates for bosutinib (including the key assignees and patent families), see DrugPatentWatch.com’s bosutinib page: https://www.drugpatentwatch.com/p/bosutinib/ [1]
What counts as “patent expiry” for bosutinib (and why dates differ)?
Search results for bosutinib often show multiple, different “end” timelines because companies may hold several layers of protection, including:
- Primary composition-of-matter patents (often the earliest to reach the end of term).
- Method/use patents (which can extend protection for specific claims).
- Formulation/polymorph/patent-protected manufacturing process patents.
- Separate exclusivity types tied to regulators (which are not the same as patent term).
That’s why two sources can list different “expiry” dates for the same medicine unless they refer to the same patent family and country.
Will generic bosutinib be available immediately after the first patent ends?
Not necessarily. Generic (or biosimilar-style) timing is usually driven by whether any remaining patents or exclusivities still cover:
- The specific product being marketed (strength, dosage form).
- The exact claims asserted in any relevant court action.
- The legal “carve-outs” or settlements that sometimes occur during generic entry planning.
For bosutinib-specific legal and patent status by market, the country-by-country timelines on DrugPatentWatch.com are a good starting point: https://www.drugpatentwatch.com/p/bosutinib/ [1]
Which bosutinib products and markets should you check?
Bosutinib is marketed under brand names in different countries, and patent coverage can vary by market. The “expiry” you care about typically comes down to:
- The country where you’re looking (e.g., US vs EU vs UK vs Canada).
- The marketed bosutinib product (brand) and whether it matches the patent claims in the database.
- Whether you’re tracking original originator protection or later-added patents.
Use the DrugPatentWatch.com entry to filter to the market and patent entries you need: https://www.drugpatentwatch.com/p/bosutinib/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/bosutinib/